These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 18609744

  • 1. Drug use and toxicity in psoriatic disease: focus on methotrexate.
    Taylor WJ, Korendowych E, Nash P, Helliwell PS, Choy E, Krueger GG, Soriano ER, McHugh NJ, Rosen CF.
    J Rheumatol; 2008 Jul; 35(7):1454-7. PubMed ID: 18609744
    [Abstract] [Full Text] [Related]

  • 2. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
    Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A.
    Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
    [Abstract] [Full Text] [Related]

  • 3. Multidisciplinary focus on methotrexate in psoriatic disesase.
    Marchesoni A, Ricci M, Moggio E, Brazzelli V, Borroni G.
    J Rheumatol Suppl; 2009 Aug; 83():56-8. PubMed ID: 19661543
    [Abstract] [Full Text] [Related]

  • 4. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages.
    Carneiro SC, Cássia FF, Lamy F, Chagas VL, Ramos-e-Silva M.
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):25-9. PubMed ID: 18181969
    [Abstract] [Full Text] [Related]

  • 5. Galactose tolerance test and methotrexate-induced liver fibrosis and cirrhosis in patients with psoriasis.
    Lenler-Petersen P, Søgård H, Thestrup-Pedersen K, Zachariae H.
    Acta Derm Venereol; 1982 Jan; 62(5):448-9. PubMed ID: 6183903
    [Abstract] [Full Text] [Related]

  • 6. Cutaneous ulceration as a sign of methotrexate toxicity.
    Del Pozo J, Martínez W, García-Silva J, Almagro M, Peña-Penabad C, Fonseca E.
    Eur J Dermatol; 2001 Jan; 11(5):450-2. PubMed ID: 11525955
    [Abstract] [Full Text] [Related]

  • 7. Psoriatic arthritis, methotrexate and the liver--are rheumatologists putting their patients at risk?
    Lindsay K, Gough A.
    Rheumatology (Oxford); 2008 Jul; 47(7):939-41. PubMed ID: 18474510
    [No Abstract] [Full Text] [Related]

  • 8. Accelerated nodulosis in a patient with psoriasis and arthritis during treatment with methotrexate.
    Berris B, Houpt JB, Tenenbaum J.
    J Rheumatol; 1995 Dec; 22(12):2359-60. PubMed ID: 8835577
    [Abstract] [Full Text] [Related]

  • 9. A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis.
    Mathew J, Leong MY, Morley N, Burt AD.
    BMC Dermatol; 2005 Nov 29; 5():12. PubMed ID: 16316460
    [Abstract] [Full Text] [Related]

  • 10. Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
    Boffa MJ, Smith A, Chalmers RJ.
    Rheumatology (Oxford); 2009 Nov 29; 48(11):1464; author reply 1465. PubMed ID: 19671697
    [No Abstract] [Full Text] [Related]

  • 11. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients.
    Wollina U, Ständer K, Barta U.
    Clin Rheumatol; 2001 Nov 29; 20(6):406-10. PubMed ID: 11771523
    [Abstract] [Full Text] [Related]

  • 12. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
    Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ.
    Can J Gastroenterol; 1996 Oct 29; 10(6):369-75. PubMed ID: 9193771
    [Abstract] [Full Text] [Related]

  • 13. [Methotrexate: safe if prescribed correctly].
    Verduijn MM, van den Bemt BJ, Dijkmans BA, van der Waal RI, Horikx A.
    Ned Tijdschr Geneeskd; 2009 Oct 29; 153():A695. PubMed ID: 19785857
    [Abstract] [Full Text] [Related]

  • 14. Visual field changes in methotrexate therapy. Case report and review of the literature.
    Sbeity ZH, Baydoun L, Schmidt S, Loeffler KU.
    J Med Liban; 2006 Oct 29; 54(3):164-7. PubMed ID: 17190135
    [Abstract] [Full Text] [Related]

  • 15. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug 29; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 16. Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
    Mease PJ, Gladman DD.
    J Rheumatol; 2011 Mar 29; 38(3):522-5. PubMed ID: 21362779
    [Abstract] [Full Text] [Related]

  • 17. Focal skin toxicity related to methotrexate sparing psoriatic plaques.
    Truchuelo T, Alcántara J, Moreno C, Vano-Galván S, Jaén P.
    Dermatol Online J; 2010 Jun 15; 16(6):16. PubMed ID: 20579471
    [Abstract] [Full Text] [Related]

  • 18. Methotrexate use in psoriasis and psoriatic arthritis.
    Cuellar ML, Espinoza LR.
    Rheum Dis Clin North Am; 1997 Nov 15; 23(4):797-809. PubMed ID: 9361156
    [Abstract] [Full Text] [Related]

  • 19. Methotrexate hepatotoxicity: what is the evidence?
    Ahern MJ, Smith MD, Roberts-Thomson PJ.
    Inflamm Res; 1998 Apr 15; 47(4):148-51. PubMed ID: 9628257
    [No Abstract] [Full Text] [Related]

  • 20. The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting.
    Rademaker M, Gupta M, Andrews M, Armour K, Baker C, Foley P, Gebauer K, George J, Rubel D, Sullivan J.
    Australas J Dermatol; 2017 Aug 15; 58(3):166-170. PubMed ID: 27402434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.